Objetivo Esophageal carcinoma (EC) is among the top 10 deadliest cancers worldwide. The current standardtherapy for ES is neoadjuvant (pre-operative) chemoradiation (NACR) followed by surgery. However,only 30% of patients achieve a complete pathological response (CPR) and long-term survival.Understanding the mechanisms of response to NACR is hence pivotal to better stratify patients andinform the design of more efficacious therapies. Evidence from some tumors suggests that NACR is“immunogenic” and stimulates anti-cancer immune responses, which may contribute to the longtermeffects of successful treatments. Tumor neo-antigens, generated by somatically mutatedcancer genes, have been recently implicated in the activation of the most efficient anti-tumor T cellresponse capable of controlling tumor progression, induced by immune checkpoint blockadeimmunotherapy. This raises the question as to whether clinical responses induced by NACR in afraction of ECs may be linked to the stimulation of clinically relevant T cell responses against tumorneoantigens, implying that activating tumor immunity in the non-responding ones may improveclinical responses. Objective of this proof-of-concept study is hence to address this question throughthe implementation of a high-throughput platform to assess neoantigen-specific T cell responses inECs in the course of NACR. Ámbito científico medical and health sciencesclinical medicinesurgerymedical and health sciencesclinical medicineoncologymedical and health sciencesbasic medicineimmunologyimmunotherapy Programa(s) H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility Tema(s) MSCA-IF-2016 - Individual Fellowships Convocatoria de propuestas H2020-MSCA-IF-2016 Consulte otros proyectos de esta convocatoria Régimen de financiación MSCA-IF-EF-SE - Society and Enterprise panel Coordinador OSPEDALE SAN RAFFAELE SRL Aportación neta de la UEn € 168 277,20 Dirección VIA OLGETTINA 60 20132 Milano Italia Ver en el mapa Región Nord-Ovest Lombardia Milano Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 168 277,20